In this issue: CHZ868, an experimental Type II JAK2 inhibitor targets inactive state of JAK2, rolls back MPN symptoms, reduces allele burden, and overcomes ruxolitinib resistance. Plus: Molecular modeling of the autoinhibitory action between the kinase and pseudokinase uncovers hidden pathogenic mechanism.
Note: Ross Levine, MD to discuss his CHZ868 work in the September 16, 2015 MPNforum Magazine
© MPN Quarterly Journal, 2015. This work is licensed under a Creative Commons Attribution-NonCommercial No-Derivs 3.0 Unported License. MPNquarterly@gmail.com